What is the purpose of the new revolving credit agreement?

The new $2.750 billion revolving credit agreement provides Boston Scientific with continued access to liquidity, which can be used for general corporate purposes, strategic investments, or to manage working capital needs. It replaces an older agreement, indicating a refinancing or modernization of the company's credit facilities.

What are the key financial covenants associated with this new credit agreement?

The agreement includes a Maximum Leverage Ratio that begins at 4.25x for the fiscal quarter ending June 30, 2021, and is set to decrease over time to 3.75x. A temporary increase to 4.75x is permitted following a significant acquisition (Qualified Acquisition) exceeding $1 billion, with subsequent step-downs. The company can also exclude certain expenses from Consolidated EBITDA calculations, providing some flexibility.

Does this new credit agreement signal any immediate financial distress for Boston Scientific?

No, the execution of a new, larger revolving credit facility typically signals proactive financial management and a desire to ensure ample liquidity and favorable borrowing terms. Replacing an existing agreement is a common practice for companies to update terms, maturities, and potentially secure better rates or covenants. The covenants, while present, seem designed to allow for strategic flexibility, including potential acquisitions.

What is the interest rate structure for loans under the new agreement?

Loans will bear interest based on either the Eurocurrency Rate or the Alternate Base Rate (ABR), plus an applicable margin. This margin is determined by Boston Scientific's Credit Rating for its long-term senior unsecured debt. There are also provisions for Multicurrency Loans and Competitive Advance Facility (CAF) Advances.

BSX 8-K: Material Agreements & Financial Events

Summary

Boston Scientific Corporation (BSX) has announced the execution of a new $2.750 billion revolving credit agreement, dated May 10, 2021, replacing its previous 2018 agreement. This new facility matures on May 10, 2026, with options for one-year extensions. The agreement provides the company with significant financial flexibility for its ongoing operations and strategic initiatives. The new credit facility includes customary covenants and events of default. Notably, it sets a maximum leverage ratio that adjusts over time and provides flexibility for certain exclusions from Consolidated EBITDA, such as non-cash charges, a limited amount of cash litigation payments, and restructuring charges. This move suggests the company is proactively managing its capital structure and ensuring access to liquidity.

Key Highlights

1Entered into a new $2.750 billion revolving credit agreement on May 10, 2021.
2The new agreement matures on May 10, 2026, with one-year extension options.
3Replaced the previous revolving credit agreement dated December 19, 2018.
4Interest rates are based on the Eurocurrency Rate or Alternate Base Rate plus an applicable margin tied to the company's Credit Rating.
5Includes a facility fee based on Credit Rating and total revolving credit commitments.
6Establishes a Maximum Leverage Ratio starting at 4.25x for Q2 2021, stepping down over time.
7Allows for a higher Maximum Leverage Ratio (up to 4.75x) following a Qualified Acquisition exceeding $1 billion.

BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (May 13, 2021)

Summary

Key Highlights

Frequently Asked Questions